Cassava Sciences | PTIE - Selling And Administration Expenses


Cassava Sciences reported $3.89M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Abbott USD 3.6B 330M Jun/2026
Amgen USD 1.72B 134M Jun/2026
Biogen USD 709.7M 155.4M Jun/2026
Cara Therapeutics USD 2.09M 96K Mar/2026
Cassava Sciences USD 3.89M 2.77M Mar/2026
Eisai JPY 114.83B 4.71B Jun/2026
Eli Lilly USD 2.93B 198M Mar/2026
Geron USD 35.42M 6.24M Mar/2026
J&J USD 6.42B 381M Jun/2026
Merck USD 2.67B 180M Mar/2026
Novartis USD 3.24B 101M Jun/2026
Novavax USD 25.53M 1.34M Dec/2025
Pfizer USD 3.41B 496M Jun/2026
Roche Holding CHF 6.37B 908M Jun/2026